Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03113643
Title SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

mature T-cell and NK-cell lymphoma

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Azacitidine + Tagraxofusp-erzs + Venetoclax

Azacitidine + Tagraxofusp-erzs

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.